Pedro A. Muñoz | PharmaMar has just announced positive results for its APLICOV trial with Aplidin against COVID-19. This antiviral achieves the primary safety objective and the secondary efficacy goal, as well as a significant reduction in viral load and C-reactive protein (CRP) in hospitalized patients. A few days before this news, the company’s president, José María Fernández Sousa-Faro, gave an interview to The Corner.